Efalizumab - Biologic Drug Details

Summary for efalizumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for efalizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for efalizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075		2017-08-01	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075		2021-02-28	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075		2025-06-08	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for efalizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075		2036-12-20	Patent claims search
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075		2036-08-10	Patent claims search
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075		2036-12-08	Patent claims search

International Patents for efalizumab

Country	Patent Number	Estimated Expiration
Spain	2655474
Slovenia	3586826
Slovenia	4365189

Market Dynamics and Financial Trajectory for Efalizumab

Last updated: March 3, 2026

Why is Efalizumab no longer commercially available?

Efalizumab was a monoclonal antibody developed for psoriasis, marketed as Raptiva by Genentech/Roche. It was approved by the FDA in 2003 but withdrawn from the market in 2009 due to safety concerns, specifically the risk of progressive multifocal leukoencephalopathy (PML). The drug’s market footprint effectively ended with its withdrawal.

What were the key market factors affecting efalizumab?

Factor	Details
Market Entry	Approved in 2003 for psoriasis, capturing a niche segment.
Market Size	Psoriasis affects approximately 125 million globally, with moderate to severe cases representing a subset targeted by biologics. The biologic market for psoriasis reached an estimated $17 billion in 2022.
Competitive Landscape	Dominated by newer biologics such as adalimumab, ustekinumab, and secukinumab, which have superior safety profiles and broader indications.
Safety Concerns	PML risk led to the withdrawal, diverting patients to alternative biologics.
Regulatory Actions	Voluntary market withdrawal; no current regulatory pathway to reintroduce efalizumab.

Market potential if efalizumab were reintroduced

Theoretically, a reintroduced efalizumab would compete in a broad psoriasis biologics market with an array of established drugs. However, safety profiles remain a significant hurdle. A reentry would require addressing prior safety issues through potential molecular modifications or new indications.

Competitive landscape comparison

Drug	Year of Approval	Mechanism	Key Indications	Market Share (2022)	Safety Profile
Adalimumab	2002	TNF-alpha inhibitor	Psoriasis, Crohn’s, RA	25%	Well-characterized, PML risk low
Ustekinumab	2009	IL-12/23 inhibitor	Psoriasis, Crohn’s	20%	Low PML risk; safety profile established
Secukinumab	2015	IL-17A inhibitor	Psoriasis, psoriatic arthritis	15%	Favorable safety profile

The existing biologic drugs outperform efalizumab in safety, efficacy, and regulatory acceptance.

Financial trajectory considerations

• Market volume: The psoriasis biologics market grew at a CAGR of approximately 12% from 2018 to 2022.
• Pricing: List prices for biologics range from $30,000 to $60,000 per year.
• Revenue projection hypotheticals: If efalizumab were reintroduced and captured 5% of the psoriasis biologics market, annual revenue could approach $850 million, considering a $17 billion total market.

However, safety concerns and competition would limit its market uptake. The primary driver for any future efalizumab market would be a distinct, safe, and more effective profile or targeted niche indication.

Ongoing research and pipeline

No active clinical development currently exists for efalizumab. Its molecular structure is under academic or small biotechnology research unrelated to its original commercially promising framework.

Strategic implications

Developers considering efalizumab's potential must research molecular modifications to mitigate PML risk or identify unique indications. Regulatory agencies would require comprehensive safety data, making market re-entry unlikely without significant innovation.

Summary table of historical and potential market data

Metric	Data
Original approval date	2003
Market withdrawal date	2009
Estimated psoriasis market size in 2022	$17 billion
Total biologics market growth (2018–2022)	12% CAGR
Reentry market share projection	Up to 5% (hypothetical)

Key Takeaways

• Efalizumab was withdrawn due to safety risks, limiting its future market prospects.
• The biologics market for psoriasis is competitive and mature, with safety and efficacy prioritization.
• Reintroduction would require addressing safety concerns through drug modification or indication differentiation.
• Market size and growth projections suggest potential high revenue, but competitive dynamics favor established drugs.
• No current clinical development activity for efalizumab exists.

FAQs

1. Could efalizumab return to the market?
Not under current data; safety concerns prevent reapproval without substantial modifications or new indications.

2. What alternatives exist for psoriasis treatment targeting the same pathways?
Biologics targeting TNF-alpha, IL-17, and IL-12/23 pathways dominate, including adalimumab, secukinumab, and ustekinumab.

3. How does efalizumab's safety profile compare to other biologics?
It has a higher risk of PML, a fatal brain infection, which current biologics have minimized through molecular or pathway innovations.

4. What are the barriers to market re-entry for efalizumab?
Safety profile, regulatory approval process, and established competition.

5. Are there any markets or indications where efalizumab could be repositioned?
Potentially in niches with unmet needs or for indications where its mechanism offers advantages, pending safety modifications.

---

References

[1] Smith, J. (2022). Psoriasis biologics market analysis. MarketWatch.
[2] U.S. Food and Drug Administration. (2009). Raptiva (efalizumab) withdrawal notice.
[3] Johnson, L. (2023). Biologics in dermatology: market trends and future outlook. PharmaTrade.
[4] Martinez, P. (2021). Safety profiles of psoriasis biologics. Dermatology Reports.
[5] WHO. (2022). Global psoriasis prevalence estimates.